AU2016289474C1 - HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents - Google Patents

HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents Download PDF

Info

Publication number
AU2016289474C1
AU2016289474C1 AU2016289474A AU2016289474A AU2016289474C1 AU 2016289474 C1 AU2016289474 C1 AU 2016289474C1 AU 2016289474 A AU2016289474 A AU 2016289474A AU 2016289474 A AU2016289474 A AU 2016289474A AU 2016289474 C1 AU2016289474 C1 AU 2016289474C1
Authority
AU
Australia
Prior art keywords
group
complex
compound
bone
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016289474A
Other languages
English (en)
Other versions
AU2016289474A1 (en
AU2016289474B2 (en
Inventor
Seok Rye Choi
Hank F. Kung
Karl Ploessl
Zehui WU
Zhihao ZHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Eleven Pharma Inc
Original Assignee
Five Eleven Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Eleven Pharma Inc filed Critical Five Eleven Pharma Inc
Publication of AU2016289474A1 publication Critical patent/AU2016289474A1/en
Publication of AU2016289474B2 publication Critical patent/AU2016289474B2/en
Application granted granted Critical
Publication of AU2016289474C1 publication Critical patent/AU2016289474C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiology & Medical Imaging (AREA)
  • Steroid Compounds (AREA)
AU2016289474A 2015-07-07 2016-07-06 HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents Active AU2016289474C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US62/189,652 2015-07-07
US201662320296P 2016-04-08 2016-04-08
US62/320,296 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (3)

Publication Number Publication Date
AU2016289474A1 AU2016289474A1 (en) 2018-02-01
AU2016289474B2 AU2016289474B2 (en) 2020-12-24
AU2016289474C1 true AU2016289474C1 (en) 2021-04-08

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016289474A Active AU2016289474C1 (en) 2015-07-07 2016-07-06 HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Country Status (11)

Country Link
US (1) US10253052B2 (enExample)
EP (1) EP3319643B1 (enExample)
JP (1) JP6792875B2 (enExample)
KR (1) KR102651945B1 (enExample)
CN (1) CN107847618B (enExample)
AU (1) AU2016289474C1 (enExample)
DK (1) DK3319643T3 (enExample)
EA (1) EA201890221A1 (enExample)
IL (1) IL256726A (enExample)
MX (1) MX377208B (enExample)
WO (1) WO2017007790A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3319643T3 (da) 2015-07-07 2020-06-15 Five Eleven Pharma Inc HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler
WO2018160544A1 (en) * 2017-03-02 2018-09-07 Five Eleven Pharma Inc. Radiopharmaceutical labeling device
WO2020028825A1 (en) * 2018-08-03 2020-02-06 Board Of Regents, The University Of Texas System Method for extraction and purification of 68ga
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
US20230001027A1 (en) * 2019-10-01 2023-01-05 City Of Hope Metal chelating agents and methods of using the same
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院(广州呼吸中心) 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院(广州呼吸中心) 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038873A1 (en) * 2011-04-13 2014-02-06 Firmenich Sa Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507001A (ja) * 2001-10-22 2005-03-10 ダウ グローバル テクノロジーズ インコーポレイティド 初期癌の治療用放射線医薬薬剤
WO2004089925A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
US7161000B2 (en) * 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2009002529A2 (en) * 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
EP2468760B1 (en) * 2009-08-20 2014-10-01 Fujifilm RI Pharma Co., Ltd. Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
DK3319643T3 (da) 2015-07-07 2020-06-15 Five Eleven Pharma Inc HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038873A1 (en) * 2011-04-13 2014-02-06 Firmenich Sa Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones

Also Published As

Publication number Publication date
JP6792875B2 (ja) 2020-12-02
AU2016289474A1 (en) 2018-02-01
WO2017007790A9 (en) 2018-01-04
CN107847618A (zh) 2018-03-27
US10253052B2 (en) 2019-04-09
IL256726A (en) 2018-03-29
DK3319643T3 (da) 2020-06-15
CA2991498A1 (en) 2017-01-12
EA201890221A1 (ru) 2018-06-29
AU2016289474B2 (en) 2020-12-24
KR102651945B1 (ko) 2024-03-26
KR20180026736A (ko) 2018-03-13
US20170022224A1 (en) 2017-01-26
WO2017007790A1 (en) 2017-01-12
CN107847618B (zh) 2021-07-16
EP3319643B1 (en) 2020-04-22
MX2018000239A (es) 2018-05-23
EP3319643A1 (en) 2018-05-16
JP2018524352A (ja) 2018-08-30
EP3319643A4 (en) 2019-04-10
MX377208B (es) 2025-03-07
HK1254864A1 (en) 2019-07-26

Similar Documents

Publication Publication Date Title
AU2023203682B2 (en) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
EP3319643B1 (en) Hbed-bisphosphonates and radiometal conjugates thereof, useful as theranostic agents
KR102870722B1 (ko) 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제
IL284963B1 (en) Diagnostic imaging agents for cancer
US20240100201A1 (en) Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases
CA2991498C (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
HK1254864B (en) Hbed-bisphosphonates and radiometal conjugates thereof, useful as theranostic agents
HK1248585B (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
HK1248585A1 (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
HK1255215B (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 DEC 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 22 DEC 2020

FGA Letters patent sealed or granted (standard patent)